Dr. Andrew J. Schuman looks at the artificial intelligence (AI) programs that may be found in your practice sooner rather than later.
FDA grants RPDD to CSTI-500 for treating pediatric Prader-Willi Syndrome
ConSynance Therapeutics' CSTI-500, an innovative Triple Monoamine Reuptake Inhibitor, has received FDA's Rare Pediatric Disease Designation for treating Prader-Willi Syndrome in children.
Food Insecurity and the Dangers of Infant Formula Dilution
FDA expands maralixibat label to include PFIC patients aged 12 months and older
Initial approval for maralixibat was granted on March 13, 2024, to treat PFIC patients aged 5 years and older.
Demystifying Infant Formula
cUTI Roundtable: The Latest Therapeutic Developments
The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.
Merck's investigational RSV monoclonal antibody clesrovimab demonstrates positive results
Merck announced clesrovimab met all primary safety and efficacy endpoints, with additional detailed findings to be presented at an upcoming scientific congress.